Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pre-diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Pre-diabetes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001552-30 Sponsor Protocol Number: PRED-D-TRIAL2015 Start Date*: 2015-10-13
    Sponsor Name:Steno Diabetes Center A/S
    Full Title: Effect of dapagliflozin, metformin and physical activity on glucose variability, body composition and cardiovascular risk in pre-diabetes (The PRE-D Trial) - A randomised, parallel, open-label, int...
    Medical condition: Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003296-18 Sponsor Protocol Number: LDX0119 Start Date*: 2020-12-30
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Effect of oral ladarixin 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatr...
    Medical condition: Obesity and pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10036481 Pre-diabetes LLT
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001663-22 Sponsor Protocol Number: na Start Date*: 2018-09-05
    Sponsor Name:Maastricht University
    Full Title: Effects of ciprofibrate on myocardial insulin sensitivity in pre-diabetes
    Medical condition: Insulin resistance, diastolic cardiac failure, mitochondrial function
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000823-15 Sponsor Protocol Number: DIASA3 Start Date*: 2019-10-18
    Sponsor Name:Oslo University Hospital
    Full Title: Glucose metabolism in South Asian women with impaired glucose tolerance or impaired fasting glucose. DIAbetes in South Asians – DIASA 3 A 12-week intervention trial with oral antidiabetic medicati...
    Medical condition: Pre-diabetes in women of South Asian ethnicity. Women of South Asian ethnicity with previous gestational diabetes, where pre-diabetes in the form of impaired glucose tolerance or impaired fasting ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002469-39 Sponsor Protocol Number: 9152 Start Date*: 2011-10-12
    Sponsor Name:Isala Klinieken
    Full Title: DIAbetes-PREvention Trial
    Medical condition: Patients who are candidates for cardiac rehabilitation after documented coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI), who have pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10064346 STEMI LLT
    14.1 100000004861 10036482 Pre-diabetic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000418-39 Sponsor Protocol Number: EPREDICE2013 Start Date*: 2015-01-20
    Sponsor Name:EVIDEM CONSULTORES SL (EVIDEM)
    Full Title: Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe
    Medical condition: Non diabetic hyperglycaemia: Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) or both
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) AT (Ongoing) ES (Ongoing) LT (Prematurely Ended) GR (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014830-10 Sponsor Protocol Number: GCPD_27july09 Start Date*: 2009-11-04
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse
    Full Title: Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone
    Medical condition: new onset diabetes mellitus after transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000650-21 Sponsor Protocol Number: PHARMADIPOAGE Start Date*: 2018-10-31
    Sponsor Name:Universidad Autónoma de Madrid
    Full Title: CLINICAL TRIAL FOR EVALUATION OF THE ADIPOQUINAS: NEW PHARMACOLOGICAL TARGETS TO PREVENT VASCULAR AGING
    Medical condition: PREDIABETES
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008287-28 Sponsor Protocol Number: ALI-FRA-0030-I Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Erlangen
    Full Title: Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes
    Medical condition: Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001049-24 Sponsor Protocol Number: NN8022-1839 Start Date*: 2008-12-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002997-31 Sponsor Protocol Number: SCH/05/015 Start Date*: 2006-08-10
    Sponsor Name:Sheffield Children's NHS Trust
    Full Title: A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis.
    Medical condition: Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. E...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000121-31 Sponsor Protocol Number: PSYK-TREAT-HEALTHY Start Date*: 2013-03-20
    Sponsor Name:Prof., dr. med. Anders Fink-Jensen
    Full Title: Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients?
    Medical condition: Dysglycaemia, schizophrenia, paranoid psycosis, schizotypal disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000671-16 Sponsor Protocol Number: BC28027 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities
    Medical condition: - Stable Cardiovascular Disease and - Diabetes Mellitus Type 2 or Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036481 Pre-diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003477-18 Sponsor Protocol Number: Empabrain01 Start Date*: 2017-05-04
    Sponsor Name:University Hospital Tuebingen
    Full Title: A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes
    Medical condition: brain insulin sensitivity in patients with prediabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000748-41 Sponsor Protocol Number: 15/135763 Start Date*: 2015-09-03
    Sponsor Name:University of Exeter
    Full Title: Autoimmune Diabetes Accelerator Prevention Trial (adAPT)
    Medical condition: Children aged 5 to 16 on entry to the RCT with the presence of two or more islet-related autoantibodies which confers a 40% risk of developing type 1 diabetes in five years.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10036481 Pre-diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023219-32 Sponsor Protocol Number: GFT505-210-6 Start Date*: Information not available in EudraCT
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety i...
    Medical condition: Patients with insulin resistance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036481 Pre-diabetes LLT
    12.1 10059179 Abdominal obesity LLT
    12.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022970-14 Sponsor Protocol Number: CACZ885M2301 Start Date*: 2011-05-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SE (Prematurely Ended) PL (Completed) LV (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) EE (Completed) GR (Completed) IS (Prematurely Ended) BE (Completed) NO (Completed) CZ (Completed) IT (Completed) BG (Prematurely Ended) SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003207-35 Sponsor Protocol Number: APCP-115,amendment Start Date*: 2013-08-13
    Sponsor Name:Karolinska University Hospital Solna
    Full Title: Effects of ARA 290, a non-hematopoietic erythropoietin analog, on glucose tolerance, insulin secretion, insulin sensitivity and long-term glucose control in individuals with prediabetes and/or dru...
    Medical condition: For the complementary visits; up to 12 Subjects with Prediabetes (impaired fasting glucose, impaired glucose tolerance) or diet-treated type 2 diabetes, will be chosen from the currently approved c...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10065542 Prediabetes LLT
    17.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 00:34:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA